T he value of 31p magnetic resonance (MR) spectroscopy for studying the substantial changes of high-energy phosphate metabolites in hearts subjected to acute ischemia and reperfusion has been extensively demonstrated in a number of animal studies.1'2 In addition, chronic alterations of energy metabolism in residual intact myocardial tissue evoked by a model of chronic myocardial infarction in rat were recently reported.3 Clinical 31p MR studies of acutely or chronically ischemic myocardium, however, have so far been few,45 and the value of 31p MR spectroscopy for patients with coronary artery disease (CAD) remains to be further defined.
Various animal models of congestive heart failure and cardiac hypertrophy have shown alterations in energy metabolism occurring in concert with reductions of mechanical function,6-8 and reduced high-energy phosphate levels have been proposed as a major mechanism responsible for the occurrence of heart failure (see Reference 9 for a review). Clinical studies based on myocardial biopsy specimens from patients with dilated cardiomyopathy (DCM) using conventional analytical biochemistry techniques'0 reported reduced myocardial ATP concentrations correlating with the extent of mechanical dysfunction. Studies on human cardiac energy metabolism using`P MR spectroscopy in patients with DCM have reported unchanged1" or reduced'2 creatine phosphate (CP)/ATP ratios.
Thus, the purpose of this study was twofold: First, we sought to define changes of energy metabolism occurring at rest in patients with CAD, specifically in those with left anterior descending coronary artery (LAD) stenosis, chronic anterior wall infarction (AWI), and posterior wall infarction (PWI). Second, to clarify con- 
Methods

Characteristics of Volunteers and Patient Groups
All studies were approved by the Ethics Committee of the University of Wurzburg. Nineteen volunteers with a mean age of 24±2 years (range, [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] years) served as a control group. All volunteers were apparently healthy individuals with no signs of heart disease at rest and during exercise. The 4 In all DCM patients, the presence of CAD was ruled out by demonstrating normal coronary anatomy in the presence of LV dysfunction by coronary angiography. In addition, none of the DCM patients had chest pain or signs of myocardial infarction on ECG readings. At the day of spectroscopy, the clinical status of each patient was evaluated by an independent cardiologist before spectroscopy was performed, and patients were graded according to the NYHA classification for heart failure. At the time of study, 16 patients received a diuretic, 16 received digitalis, 16 an ACE inhibitor, two a class I (mexiletine and propafenone) and one a class III (amiodarone) antiarrhythmic drug, and two acetylsalicylic acid. whole-body Philips Gyroscan MR system with an effective bore size of 65 cm. A single custom-made 15-cmdiameter surface coil tunable to 'H and 31p (doubletuned coil) served as both transmitter and receiver coil. To minimize motion artifacts, subjects were examined in prone position with the chest wall lying above the surface coil.
Before each measurement, shimming on the proton signal was performed, yielding line widths of <0.7 ppm (<45 Hz) for H20; spectroscopy was not performed if 'H line width could not be reduced below 0.7 ppm. Localization was then carried out by the image-selected in vivo spectroscopy (ISIS) technique.'3 First, nine Tl-weighted, spin-echo multislice 'H images of the heart were recorded with a pulse repetition time (TR) equal to one RR interval, an echo time of 30 msec, and a slice thickness of 15 mm, confirming the correct position of the surface coil relative to the heart. On the basis of these scout images, the ISIS volume was positioned over the anteroseptal region of the heart, as illustrated by an example shown in Figure 1 . Volume size for spectroscopy ranged from 46 to 117 cm3 (mean, 84+12 cm3). Adiabatic pulses were used and yielded flip angles of 1800 throughout the selected volume. The acquisition was ECG triggered. TR was equal to two RR intervals, 15 or 24 seconds; correspondingly, the number of averages was 1,024, 128, or 96; 32%, 36%, and 24% of measurements in volunteers, CAD patients, and DCM patients, respectively, were performed with a short TR (two RR intervals). Total scan time/spectrum was :32 minutes, and total patient examination time was 45-60 minutes. For the six patients with DCM studied sequentially, the same TR was used for both examinations. CP/ATP ratios were corrected for partial saturation based on T, measurements in volunteers as previously described14: Tls of y-ATP, CP, and phosphodiester (PDE) were 5.4±0.5, 6.1±0.5, and 5.0±+1.0 seconds, respectively. This assumes that T,s do not change in the presence of cardiac disease. The quality of volume selection by ISIS was tested in phantom experiments in which a cube (volume, 64 ml) filled with hypophosphoric acid (H3P02) was placed in a cylinder (15 volume by <10% regardless of TR. 3P spectra were processed with zero shift, direct current correction (30%), exponential multiplication ( Figure 2A shows a typical "P spectrum from a volunteer. The average ratio of T1-and blood-corrected CP/ATP was 1.95+0.45, and PDE/ATP was 1.06±0.53 ( Figure 3) . Values Figures 2B-2D . Compared with the volunteer, none of the spectra appear to be grossly altered apart from various degrees of blood contamination. Mean T,-and blood-corrected metabolite ratios are given in Figure 3 . The figure demonstrates that neither the CP/ATP nor the PDE/ATP ratio showed any significant change in patients with CAD, although there may be a slight tendency for reduced CP/ATP in AWI and PWI. Thus, no significant abnormalities of energy metabolism at rest could be detected in patients with LAD stenosis, AWI, and PWI. Dilated Cardiomyopathy Figure 4 (left panel) shows the spectrum of a 37-year old patient with DCM who was in NYHA class Ill heart failure. In this spectrum, the CP/ATP ratio is reduced (1.56), and the PDE/ATP ratio is elevated (2.26). Figure   3 gives of heart failure, however, a different picture evolved. As depicted in Figure 3 , CP/ATP ratios were unchanged (1.94+0.43) in patients with mild (NYHA <III) but significantly reduced (1.44+0.52; p<0.05) in severe (NYHA 2111) DCM. Figure 5 shows that the CP/ATP ratio decreased progressively in relation to the severity of heart failure; CP/ATP values were 2.14±0.32 (n=9), 1.71±0.46 (n=8), 1.61±0.31 (n=4), and 1.26±0.68 (n=4) for NYHA classes II, 11-111, III, and III-IV, respectively. Furthermore, linear regression between NYHA class and CP/ATP was highly significant (r=0.60,p<0.005). In contrast, the PDE/ATP ratio bore no correlation with the clinical severity of heart failure ( Figures 3 and 5 Finally, a subgroup of six patients with DCM was examined sequentially before and after 12±6 weeks of drug therapy (see "Methods" and Table 3 ). The six patients improved by 0.8±0.3 NYHA classes during treatment. Figure 4 shows spectra of a patient before and after therapy. The increase of CP/ATP and the decrease of PDE/ATP occurring with therapy are apparent. Figure 6 shows the changes of CP/ATP and PDE/ATP during treatment. The initial CP/ATP ratio bor p=NS atrh before after the signal originated from heart muscle. Therefore, PDE/ ATP ratios may also vary depending on the degree of blood contamination. Because all published values were obtained at 1.5-2 T, the well-described field dependence of PDE27,28 should not be a major factor influencing PDE/ATP ratios.
Coronary Artery Disease
In patients with LAD stenosis, we studied energy metabolism of myocardium supplied by a highly stenotic coronary artery at rest. Normal metabolite ratios indicate that alterations of energy metabolism do not occur under these conditions. This is in agreement with the findings of Weiss et al,4 who reported normal CP/ATP in anterior myocardium supplied by a stenotic LAD. In addition, these authors demonstrated that the CP/ATP ratio decreased significantly during exercise. We also found normal CP/ATP and PDE/ATP in patients with AWI and PWI. In AWI, because of a relatively large selected volume (up to 114 cm3), we obtained signal from residual myocardium adjacent to the infarct zone and from scar tissue. Since myocardial scar tissue presumably contains little or almost no ATP, however, the acquired signal most likely arose almost exclusively from residual intact myocardium. In PWI patients, spectra from residual intact myocardium remote from the infarct scar were acquired. Normal metabolite ratios in AWI and PWI patients indicate that energy metabolism at rest is unaltered in residual myocardium. It remains to be determined whether such patients will show altered energy metabolism during exercise. To date, there are no other studies examining anterior wall 31P spectra after PWI. One study by Bottomley et al5 has reported reduced CP/inorganic phosphate (Pi) and increased Pi/ATP ratios in some spectra obtained from patients examined 5-9 days after AWI. In our spectra, we were unable to resolve the Pi resonance from the overlapping 2,31-DPG resonances and thus could not evaluate changes of the Pi resonance. Hardy et al'2 have reported reduced CP/ATP (1.53+±0.07 versus 1.80±0.06 in volunteers, SEM) in patients with congestive heart failure resulting from severe multivessel CAD (presumably patients who had myocardial infarctions months to years before), but none of our patients with myocardial infarction and normal CP/ATP ratios had signs of failure. Systematic sequential studies of the changes in energy metabolism after myocardial infarction in conjunction with invasive and noninvasive evaluation of 
Dilated Cardiomyopathy
In this study, we report that as a group including all clinical stages, the CP/ATP ratio in patients with DCM tended to be lower (1.78±0.51, SD) but was not significantly decreased compared with volunteers (1.95± 0.45). When patients were subdivided according to the clinical severity of heart failure, however, the CP/ATP ratio was progressively-reduced. There was no significant change in patients with mild heart failure, but there was a marked reduction of CP/ATP in advanced stages of heart failure. CP/ATP ratios showed a highly significant correlation with the NYHA class (p<0.005). No correlation could be detected between measurements of LV function (FS, EF) and CP/ATP or PDE/ATP ratios. The presence of a correlation of CP/ATP with the clinical status in the absence of a correlation with direct functional indexes may be related to the fact that not all DCM patients with low EFs immediately develop the full clinical syndrome of heart failure. The clinical syndrome of severe heart failure is characterized by neurohumoral activation, and it is likely that this was the case in DCM patients with severe heart failure, whereas DCM patients with discrete signs of heart failure have only slightly elevated catecholamine, renin, and vasopressin levels. 29, 30 Changes in high-energy phosphate metabolism of the heart may therefore be dependent in part on the full clinical syndrome of congestive heart failure, including neurohumoral activation and sodium and water retention. Our findings are in line with the few reports available on this issue.
Hardy et al'2 reported reduced CP/ATP (1.41+0.12 versus 1.80±0.06 in volunteers, SEM) in patients with DCM and overt cardiac failure; these authors also were unable to demonstrate a correlation of LVEF and CP/ATP or PDE/ATP. Reduced CP/ATP ratios have also been described by Luyten et 46 and 114 ml; using computer simulation, Lawry et a142 have shown that, in an ISIS experiment, the degree of contamination from signal outside the selected volume may depend on the size of the selected volume itself. We selected the ISIS volume to include as much heart muscle as possible and cannot exclude the possibility that such effects might constitute an error source. It should also be mentioned that all spectra were obtained at rest, and establishment of routine exercise standards should greatly enhance the sensitivity of the technique for detecting diseased myocardium.4,43 Finally, the approach of blood-correcting spectra, which is at present taken by most groups using cardiac 31p MR spectroscopy, may have certain limitations: first, blood 31p_ observable metabolites may undergo changes with disease states44; second, the Pi resonance is included in the area of the 2,3-DPG peaks, and if Pi is increased in DCM, overcorrection of the CP/ATP ratio might occur; third, the blood ATP/2,3-DPG ratio may change with the degree of oxygen saturation45 and may, thus, vary depending on the degree of right versus left chamber blood contamination. Although we would not expect any of these factors to profoundly change our results, an exact evaluation is problematic at present.
In summary, we found unchanged myocardial highenergy phosphate metabolism at rest in patients with CAD. Alterations in energy metabolism do occur in advanced but not in mild cases of DCM; such changes correlate with the severity of heart failure and can be improved with treatment leading to clinical recompensation.
